You are here: Industry Insights > Lipidor

News List

Lipidor Announces Enrolment of First Patients in a Phase III Study on AKP02 for Treatment of Psoriasis prnasia
January 29, 2022
Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) today reports that the first patients have been enrolled in a Phase III clinical study using AKP02 cutaneous spray...
Lipidor AB licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 prnasia
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug ...
Lipidor licence agreement grants Menarini Group company, RELIFE Srl, exclusive rights to register, promote, distribute and market two new psoriasis drug candidates for potential value of MEUR 70 firstwordpharma
July 02, 2021
Lipidor AB (publ) announced today that it has signed a licence agreement under which Lipidor grants RELIFE S.r.l., part of leading international pharmaceutical company, Menarini Group, exclusive rights to register, promote, distribute, and market drug.
Lipidor - update on the company's phase III clinical trial of drug candidate AKP02 for treatment of psoriasis prnasia
April 23, 2021
Lipidor AB (publ) provides an update on the planned Phase III study of the company's drug candidate AKP02 for the treatment of psoriasis. During the first quarter of 2021, Lipidor submitted an application to the Indian Medical Products Agency for ...
Lipidor's subsidiary Emollivet takes the next step towards launch and receives funding from Vinnova prnasia
April 23, 2021
Sweden's innovation authority Vinnova is investing in Lipidor's subsidiary Emollivet. The funding from Vinnova is for SEK 300,000 and will be used for a project in which Emollivet, through interaction with animal owners and others in the animal health ...
Lipidor signs cooperation agreement with contract manufacturer to offer licensees the opportunity for GMP production prnasia
December 17, 2020
Lipidor AB announced that the Company has signed a new cooperation agreement with Aurena Laboratories AB. Over a five-year period, Lipidor will invest up to SEK 15 million in the new collaboration.
Lipidor announces positive outcome of feasibility study for development of topical medical cannabis products based on the company's AKVANO® technology prnasia
October 09, 2020
Lipidor AB today announces a positive outcome of the feasibility study into the development of topical medicinal cannabis products for the treatment of skin inflammations and psoriatic lesions.
Lipidor Signs Agreement With CRO for Implementation of Phase III Clinical Study of Drug Candidate AKP-02 Against Psoriasis prnasia
July 08, 2020
Lipidor AB (Nasdaq First North: LIPI) today announced an agreement with Cadila Pharmaceuticals, a leading Indian pharmaceutical company with extensive CRO capacity, to conduct a Phase III study for Lipidor's drug candidate AKP-02. The study is expected to
Lipidor and Cadila Pharma strike partnership for psoriasis drug candidate’s phase III clinical study expresspharma
July 08, 2020
The Phase III study is expected to involve 270 patients and will be conducted in India on patients with various skin types.
Lipidor, Cadila Sign Agreement for Phase III Trial of AKP-02 contractpharma
July 08, 2020
Cadila Pharmaceuticals to conduct a Phase III study for Lipidor's anti-psoriasis candidate AKP-02.

Previous page 1 2 Next page